Dermatology Biologics & Targeted Therapies — Overview
The past decade has revolutionized dermatology with biologics and small-molecule targeted drugs. From psoriasis, atopic dermatitis, chronic urticaria, alopecia areata, hidradenitis suppurativa, to vitiligo, previously intractable moderate-to-severe diseases now have precision treatments capable of "skin clearance". This article summarizes from a patient perspective: mechanisms, dosing, frequency, NHI conditions in Taiwan, out-of-pocket costs, required pre-screening, side effects.
Biologic vs Small-Molecule Targeted Drug
- Biologics: large protein molecules (usually monoclonal antibodies); given by injection (SC or IV). Examples: Dupilumab, Adalimumab, Secukinumab, Guselkumab
- Small-molecule targeted drugs: small synthetic molecules; given orally. Examples: JAK inhibitors (Upadacitinib, Abrocitinib), PDE-4 inhibitor (Apremilast), TYK2 inhibitor (Deucravacitinib)
Atopic Dermatitis
| Drug | Mechanism | Indication | Route / Frequency | Expected efficacy |
|---|---|---|---|---|
| Dupilumab (Dupixent) | Anti-IL-4Rα (blocks IL-4 + IL-13) | ≥ 6 months moderate-severe AD | SC; 600 mg loading → 300 mg q2w | EASI-75 at week 16: 51-69% (SOLO 1/2); itch rapid improvement 1-2 wk |
| Tralokinumab (Adbry / Adtralza) | Anti-IL-13 | ≥ 12 yo moderate-severe AD | SC; 300 mg q2w | EASI-75 wk 16: 25-33% (ECZTRA) |
| Lebrikizumab (Ebglyss) | Anti-IL-13 trap | ≥ 12 yo moderate-severe AD | SC; q4w maintenance | EASI-75 wk 16: 51-59% (ADvocate) |
| Upadacitinib (Rinvoq) | Selective JAK1 | ≥ 12 yo moderate-severe AD | Oral; 15-30 mg/d | EASI-75 wk 16: 60-80% (Measure Up); rapid onset |
| Abrocitinib (Cibinqo) | Selective JAK1 | ≥ 12 yo moderate-severe AD | Oral; 100-200 mg/d | EASI-75 wk 12: 40-63% (JADE) |
| Baricitinib (Olumiant) | JAK1/2 | AD (Europe; not in Taiwan AD indication) | Oral 2-4 mg/d | EASI-75 wk 16: 25-30% (BREEZE-AD) |
JAK Inhibitor Pre-treatment Screening (2024 German S3 AD guideline)
Required before Abrocitinib / Baricitinib / Upadacitinib:
Required before Abrocitinib / Baricitinib / Upadacitinib:
- TB screening: chest X-ray within 3 mo + IGRA. If latent TB: prophylaxis (isoniazid 9 mo or rifampin 4 mo)
- Hepatitis B / C, HIV, CBC, LFT, lipid panel (TC / LDL / HDL / TG), CPK
- Absolute contraindication thresholds: ALC < 500/μL, ANC < 1000/μL, Hb < 8 g/dL
- Verify vaccination status; no live vaccines after starting
- VTE high risk (DVT / PE history) contraindicated (class warning from ORAL Surveillance in RA)
- Monitor: URI, HSV recurrence, acne, CPK rise, unexplained weight loss
Psoriasis
| Drug | Mechanism | Frequency | Expected efficacy (PASI 90 wk 16) | Out-of-pocket (NTD/mo) |
|---|---|---|---|---|
| IL-17 inhibitors | ||||
| Secukinumab (Cosentyx) | Anti-IL-17A | SC; loading wk 0,1,2,3,4 → q4w 300 mg | ~ 70-72% (ERASURE / FIXTURE) | 35,000-45,000 |
| Ixekizumab (Taltz) | Anti-IL-17A | SC; 160 mg loading → 80 mg q4w | ~ 70-83% (UNCOVER) | 35,000-45,000 |
| Bimekizumab (Bimzelx) | Anti-IL-17A & IL-17F | SC; 320 mg q4w → q8w | ~ 85-88% (BE READY / VIVID) | 40,000-55,000 |
| IL-23 inhibitors | ||||
| Guselkumab (Tremfya) | Anti-IL-23p19 | SC; loading wk 0,4 → q8w 100 mg | ~ 73-80% (VOYAGE 1/2) | 35,000-50,000 |
| Risankizumab (Skyrizi) | Anti-IL-23p19 | SC; loading wk 0,4 → q12w 150 mg | ~ 75-81% (UltIMMa 1/2) | 35,000-50,000 |
| Tildrakizumab (Ilumya) | Anti-IL-23p19 | SC; loading wk 0,4 → q12w 100 mg | ~ 56-66% (reSURFACE) | 30,000-40,000 |
| TNF inhibitors | ||||
| Adalimumab (Humira) | Anti-TNFα | SC; 80 mg loading → 40 mg q2w | ~ 50-60% | 15,000-25,000 (biosimilar) |
| Etanercept (Enbrel) | TNFR-Fc | SC; 50 mg q1w | ~ 30-40% | 20,000-30,000 |
| Oral small molecules | ||||
| Apremilast (Otezla) | PDE-4 inhibitor | Oral 30 mg BID | PASI 75 ~ 30-35% | 20,000-28,000 |
| Deucravacitinib (Sotyktu) | Selective TYK2 | Oral 6 mg/d | PASI 90 wk 16 ~ 40% (POETYK PSO-1) | 30,000-40,000 |
Alopecia Areata
| Drug | Mechanism | Indication | Dose | Phase-3 efficacy |
|---|---|---|---|---|
| Baricitinib (Olumiant) | JAK1/2 | Adults ≥ 18 severe AA | Oral 4 mg/d | SALT ≤ 20 wk 36: 38.8% (BRAVE-AA1/2) |
| Ritlecitinib (Litfulo) | JAK3 / TEC | ≥ 12 yo severe AA | Oral 200 mg loading × 4 wk → 50 mg/d | SALT ≤ 20 wk 24: 31% (200/50) / 23% (50) |
Chronic Spontaneous Urticaria (CSU)
- Omalizumab (Xolair): anti-IgE, SC 300 mg q4w (off-label up to 600 mg q2w if no response). Conditionally NHI-covered. Pipeline: BTK inhibitors (Remibrutinib, Rilzabrutinib), Dupilumab.
Hidradenitis Suppurativa (HS)
- Adalimumab: SC 40 mg weekly (note: 2024 update — was bi-weekly previously). PIONEER I/II Hi-SCR ~50% at 12 wk. NHI conditional.
- Secukinumab also approved (2023); 300 mg q4w after loading.
Vitiligo
- Topical Ruxolitinib 1.5% cream (Opzelura): JAK1/2 inhibitor, BID. T-VASI50 wk 24 ~ 50% (TRuE-V1/V2). Out-of-pocket in Taiwan.
Pre-Treatment Screening Checklist
- TB: chest X-ray + IGRA (or PPD)
- Hepatitis B / C, HIV
- CBC, AST/ALT, creatinine, lipid panel
- Pregnancy test (women of reproductive age)
- Vaccination history (avoid live vaccines while on biologic / JAK)
- Detailed history: heart failure, DVT, malignancy, recurrent infections, multiple sclerosis
Summary
Biologics and targeted small-molecule drugs have transformed moderate-to-severe inflammatory skin disease care. The right drug for the right disease, with proper screening and monitoring, is dramatically better than long-term systemic steroids or repeated topicals. Discuss with your dermatologist about which option matches your disease, comorbidities, and personal preferences.